IN2014DN07636A - - Google Patents

Download PDF

Info

Publication number
IN2014DN07636A
IN2014DN07636A IN7636DEN2014A IN2014DN07636A IN 2014DN07636 A IN2014DN07636 A IN 2014DN07636A IN 7636DEN2014 A IN7636DEN2014 A IN 7636DEN2014A IN 2014DN07636 A IN2014DN07636 A IN 2014DN07636A
Authority
IN
India
Prior art keywords
compounds
liver
receptor
disease
compositions
Prior art date
Application number
Inventor
Chengguo Dong
Yi Fan
Katerina Leftheris
Stephen Lotesta
Suresh B Singh
Colin Tice
Wei Zhao
Yajun Zheng
Linghang Zhuang
Original Assignee
Vitae Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc
Publication of IN2014DN07636A publication Critical patent/IN2014DN07636A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described.
IN7636DEN2014 2012-03-16 2013-03-14 IN2014DN07636A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261612051P 2012-03-16 2012-03-16
PCT/US2013/031242 WO2013138565A1 (en) 2012-03-16 2013-03-14 Liver x receptor modulators

Publications (1)

Publication Number Publication Date
IN2014DN07636A true IN2014DN07636A (en) 2015-05-15

Family

ID=47997957

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7636DEN2014 IN2014DN07636A (en) 2012-03-16 2013-03-14

Country Status (28)

Country Link
US (4) US9006244B2 (en)
EP (1) EP2825541B1 (en)
JP (3) JP6114814B2 (en)
KR (1) KR102069912B1 (en)
CN (1) CN104203951B (en)
AU (1) AU2013232066B2 (en)
CA (1) CA2866218C (en)
CY (1) CY1118318T1 (en)
DK (1) DK2825541T3 (en)
EA (1) EA026907B1 (en)
ES (1) ES2598653T3 (en)
HK (1) HK1206333A1 (en)
HR (1) HRP20161196T1 (en)
HU (1) HUE029402T2 (en)
IL (1) IL234265B (en)
IN (1) IN2014DN07636A (en)
LT (1) LT2825541T (en)
ME (1) ME02534B (en)
MX (1) MX354818B (en)
NZ (1) NZ629122A (en)
PL (1) PL2825541T3 (en)
PT (1) PT2825541T (en)
RS (1) RS55166B1 (en)
SG (1) SG11201405328SA (en)
SI (1) SI2825541T1 (en)
SM (1) SMT201600374B (en)
WO (1) WO2013138565A1 (en)
ZA (1) ZA201406326B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026907B1 (en) * 2012-03-16 2017-05-31 Вайтаи Фармасьютиклз, Инк. Liver x receptor modulators
KR102069913B1 (en) * 2012-03-16 2020-01-23 비타이 파마슈티컬즈, 엘엘씨 Liver x receptor modulators
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
US20170231992A1 (en) * 2014-06-19 2017-08-17 Vitae Pharmaceuticals, Inc. Compounds for use in treating acute coronary syndrome and related conditions
BR112017002260A2 (en) * 2014-08-07 2017-11-21 Vitae Pharmaceuticals Inc piperazine derivatives as liver receptor x modulators
US20190125745A1 (en) * 2014-12-17 2019-05-02 Rgenix, Inc. Treatment and diagnosis of cancer
CN105017262B (en) * 2015-07-07 2017-05-03 广东也乐新材料制造有限公司 Synthetic method of aldehyde multi-substituted heterocyclic aromatic hydrocarbon compound
CN105288658B (en) * 2015-10-30 2018-08-28 中国人民解放军第三军医大学 MiR-18a-5p inhibitor is preparing the application in preventing medicine for treating osteoporosis
JP7025022B2 (en) 2016-01-11 2022-02-24 ザ ロックフェラー ユニバーシティー Methods for the treatment of myeloid-derived inhibitory cell-related disorders
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
AU2020401286A1 (en) 2019-12-13 2022-06-23 Inspirna, Inc. Metal salts and uses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748247A (en) 1986-10-21 1988-05-31 American Home Products Corporation 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists
EP0511993A1 (en) 1990-01-22 1992-11-11 E.I. Du Pont De Nemours And Company Herbicidal sulfonylureas
EP0572863A1 (en) 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag CNS pyrazinoindoles
JP3998261B2 (en) 1993-12-23 2007-10-24 イーライ・リリー・アンド・カンパニー Protein kinase C inhibitor
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
WO1996012721A1 (en) 1994-10-20 1996-05-02 American Home Products Corporation Indole derivatives useful as serotonergic agents
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2257950A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
CA2257937A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
EP0912175A4 (en) 1996-06-28 1999-09-08 Merck & Co Inc Fibrinogen receptor antagonists
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
FR2761073B1 (en) * 1997-03-20 1999-04-23 Synthelabo PYRAZINO [1,2-A] INDOLE-1-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2761070B1 (en) 1997-03-20 1999-04-23 Synthelabo DIHYDROPYRAZINO [1,2-A] INDOLE-1-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
DE19802235A1 (en) 1998-01-22 1999-07-29 Bayer Ag New oxazolidinone derivatives useful as antibacterial agents for treating local or systemic infections in humans or animals
ID23219A (en) 1998-04-17 2000-03-30 Lilly Co Eli SUBSTITUTED TRISICLIC
ATE289593T1 (en) 1999-05-06 2005-03-15 Neurogen Corp SUBSTITUTED 4-OXO-QUINOLINE-3-CARBOXAMIDE AS GABA BRAIN RECEPTOR LIGANDS
US7037916B2 (en) 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
IT1313593B1 (en) 1999-08-03 2002-09-09 Novuspharma Spa 1,2-DIIDRO-1-OXO-PIRAZINO 1,2-A INDOL DERIVATIVES.
WO2001030331A2 (en) 1999-10-22 2001-05-03 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
CA2396257A1 (en) 2000-01-06 2001-07-12 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Novel compounds and compositions as protease inhibitors
DK1325008T3 (en) 2000-07-31 2006-02-13 Hoffmann La Roche piperazine
JP2005506280A (en) 2000-12-20 2005-03-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー Aryl and aminoaryl substituted serotonin receptor agonists and antagonist ligands
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
FR2829766A1 (en) 2001-09-14 2003-03-21 Lipha Composition useful in the treatment of pathologies associated with e.g. hyperglycemia, diabetes, dyslipidemia, obesity, arterial hypertension, neuropathies, and nephropathies, comprises oxamate derivatives
BR0215288A (en) 2001-12-21 2004-12-21 King Phamaceuticals Res & Dev Compound, pharmaceutically acceptable salts thereof, and methods for identifying tumor cells rich in p2x7 receptors, purinergic in a mammal, to treat a medical condition in a mammal, and to induce apoptosis in neoplastic cells in a patient
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
DE10320780A1 (en) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituted dihydroquinazolines
ES2564804T3 (en) 2004-02-12 2016-03-29 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
US20070232658A1 (en) 2004-04-08 2007-10-04 Jurgen Wagner Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction
RU2266906C1 (en) 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Anellated carbamoyl azaheterocycles, methods for their preparing (variants), pharmaceutical composition, focused library
ITMI20040874A1 (en) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori INDOLIC AND AZAINDOLIC DERIVATIVES WITH ANTI-TUMORAL ACTION
WO2005113526A2 (en) 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
DE602005019465D1 (en) 2004-12-15 2010-04-01 Hoffmann La Roche BI- AND TRICYCLIC SUBSTITUTED PHENYL-METHANONE AS INHIBITORS OF GLYCIN-I (GLYT-1) TRANSPORTERS FOR THE TREATMENT OF ALZHEIMER DISEASE
US20090238761A1 (en) 2005-01-03 2009-09-24 Universita Degli Studi Di Siena Novel Aryl Piperazine Derivatives With Medical Utility
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
JP4927079B2 (en) 2005-07-14 2012-05-09 エフ．ホフマン−ラ ロシュ アーゲー Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1A receptor antagonists
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
JP2007137810A (en) * 2005-11-17 2007-06-07 Sankyo Co Ltd Medicine containing indole compound
EP1960401B1 (en) 2005-12-09 2009-11-11 F.Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
US7351706B2 (en) 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
FR2897061B1 (en) * 2006-02-03 2010-09-03 Sanofi Aventis TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE PATTERN, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
RU2318818C1 (en) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Azaheterocycles, combinatory library, focused library, pharmaceutical composition and method for preparing (variants)
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CN101679220A (en) 2007-04-09 2010-03-24 梅特希尔基因公司 Histone deacetylase inhibitor
KR20100040872A (en) 2007-06-25 2010-04-21 뉴로젠 코포레이션 Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
US20100197657A1 (en) 2007-09-25 2010-08-05 Chang Ronald K 2-aryl or heteroaryl indole derivatives
CN101456863B (en) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Novel LXR agonist as well as preparation method and application thereof
AU2008345687A1 (en) * 2007-12-21 2009-07-09 Wyeth Llc Pyrazolo [1,5-a] pyrimidine compounds
EA201070876A1 (en) 2008-01-22 2011-04-29 Такеда Фармасьютикал Компани Лимитед TRICYCLIC COMPOUNDS, HAVING ANTAGONISTIC ACTIVITY WITH RESPECT TO CORTICOTROPIN-RELAXING FACTOR, AND THEIR PHARMACEUTICAL COMPOSITIONS
WO2009097515A2 (en) 2008-01-30 2009-08-06 Wyeth [a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
US8207165B2 (en) 2008-03-28 2012-06-26 Nerviano Medical Sciences S.R.L. 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TW201031665A (en) 2009-02-04 2010-09-01 Gruenenthal Gmbh Substituted indole-compound
AU2010257856A1 (en) 2009-06-08 2011-11-03 Grünenthal GmbH Substituted benzimidazoles, benzothiazoles and benzoxazoles
WO2011005295A1 (en) 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
CN102596955A (en) 2009-09-11 2012-07-18 桑诺维恩药品公司 Histamine H3 inverse agonists and antagonists and methods of use thereof
EP2509979B1 (en) 2009-12-07 2016-05-25 Boehringer Ingelheim International GmbH Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
US8654867B2 (en) 2011-12-07 2014-02-18 Texas Instruments Incorporated Transformer power combiner with filter response
KR102069913B1 (en) 2012-03-16 2020-01-23 비타이 파마슈티컬즈, 엘엘씨 Liver x receptor modulators
EA026907B1 (en) * 2012-03-16 2017-05-31 Вайтаи Фармасьютиклз, Инк. Liver x receptor modulators

Also Published As

Publication number Publication date
JP6114814B2 (en) 2017-04-12
EA026907B1 (en) 2017-05-31
HRP20161196T1 (en) 2016-11-04
ZA201406326B (en) 2019-11-27
JP2015510892A (en) 2015-04-13
AU2013232066B2 (en) 2017-07-06
KR102069912B1 (en) 2020-01-23
HUE029402T2 (en) 2017-02-28
PL2825541T3 (en) 2016-12-30
US20150080406A1 (en) 2015-03-19
RS55166B1 (en) 2017-01-31
CN104203951A (en) 2014-12-10
MX354818B (en) 2018-03-21
PT2825541T (en) 2016-09-28
EP2825541A1 (en) 2015-01-21
JP2019023196A (en) 2019-02-14
SI2825541T1 (en) 2016-10-28
US9814715B2 (en) 2017-11-14
WO2013138565A1 (en) 2013-09-19
US9006244B2 (en) 2015-04-14
CN104203951B (en) 2016-11-02
US9388190B2 (en) 2016-07-12
CY1118318T1 (en) 2017-06-28
EA201491609A1 (en) 2014-12-30
CA2866218A1 (en) 2013-09-19
DK2825541T3 (en) 2016-10-03
SMT201600374B (en) 2016-11-10
KR20140139555A (en) 2014-12-05
LT2825541T (en) 2016-12-27
ES2598653T3 (en) 2017-01-30
HK1206333A1 (en) 2016-01-08
CA2866218C (en) 2020-06-09
SG11201405328SA (en) 2014-11-27
MX2014011103A (en) 2014-12-05
US9006245B2 (en) 2015-04-14
US20150051214A1 (en) 2015-02-19
EP2825541B1 (en) 2016-06-22
US20170136017A1 (en) 2017-05-18
IL234265B (en) 2020-06-30
AU2013232066A1 (en) 2014-09-11
JP2017128588A (en) 2017-07-27
ME02534B (en) 2017-02-20
NZ629122A (en) 2016-04-29
US20150246924A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
IN2014DN07636A (en)
MX2014011104A (en) Liver x reception modulators.
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
IL267696A (en) Compositions, methods, and systems for the synthesis and use of imaging agents
PH12017501176A1 (en) Pyruvate kinase activators for use therapy
MX2021011939A (en) Neuroactive compounds and methods of use thereof.
PH12014502704A1 (en) Compounds and compositions for modulating egfr activity
MX359327B (en) Methods and compositions for treating huntington's disease.
CL2013003313A1 (en) Compounds derived from pharmaceutically acceptable 2,4-diaminoquinazolines, salts or solvates; pharmaceutical composition comprising them; and use in the treatment of a disorder involving the modulation of tlr7 and / or tlr8.
GB201017345D0 (en) Receptor antagonists
EA201591805A1 (en) OXABICICLO [2.2.2] ACIDS - MODULATORS GPR120
PH12014502032A1 (en) Treatment of brain cancer
MX361349B (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions.
TN2014000136A1 (en) Selective androgen receptor modulators
IN2014KN02993A (en)
MX2015003899A (en) Modulators of androgen synthesis.
EP2881397A4 (en) Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor
MX2016002931A (en) Liver x receptor (lxr) modulators.
MX2015012043A (en) Muscarinic agonists.
MX351961B (en) Diazonamide analogs.
MX2015001134A (en) Therapeutic compounds.